See www.DynamicMedical.com for the latest version as DynaMed is updated daily
You are viewing a DynaMed summary. Use of DynaMed indicates acceptance of DynaMed Terms of Use. Limitations of DynaMed are contained in the DynaMed Terms of Use. To search within this summary, click Expand All, and then Edit - Find (Ctrl-F) in your browser.
Meniere's disease
Updated 2008 Aug 11 11:29 AM: review article notation (Lancet 2008 Aug 2) Links added to drug topics vestibular rehabilitation may improve subjective dizziness in patients with unilateral peripheral vestibular dysfunction (Cochrane Library 2007 Issue 4)
General Information (including ICD-9/-10 Codes)
Description:
z rare idiopathic disorder of inner ear characterized by recurrent, spontaneous
Also called:
z Meniere's syndrome (if secondary to known cause)
ICD-9 Codes:
{ 386.01 active Meniere's disease, cochleovestibular
{ 386.02 active Meniere's disease, cochlear
{ 386.03 active Meniere's disease, vestibular
ICD-10 Codes: Organs Involved:
z inner ear, specifically cochlea, vestibular apparatus and membranous
z rates of bilateral involvement reported to vary from 2% to 78%(1,2 )
Who is most affected:
z reviews vary regarding ages of peak onset
{ ages 40-60 years (Acta Otolaryngol 1985 Mar-Apr;99(3-4):445 as
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
z may affect women more often than men (1.3:1)(2 ) or may affect men and
Incidence/Prevalence:
true incidence unknown due to inconsistency in establishing diagnosis(1 )
z estimated prevalence of Meniere's disease
{ 157 per 100,000 persons in United Kingdom
References - Laryngoscope 1983 Sep;93(9):1217 as referenced in(2 ),
Acta Otolaryngol Suppl 1995;519:206, Arch Otolaryngol 1978 Feb;104(2):99
z annual age-adjusted incidence 15.3 per 100,000 in Rochester, Minnesota (1951-1980)
{ based on 180 cases of Meniere's disease identified over 30 years
{ slight female preponderance (16.3:13.3) but not significant
{ Reference - Laryngoscope 1984 Aug;94(8):1098
z most common causes of vertigo in general practice are benign positional vertigo, acute vestibular neuronitis, and Meniere's disease
{ these 3 diagnoses accounted for 93% diagnoses among 70 patients
with vertigo presenting to 13 general practitioners in prospective
{ Reference - Br J Gen Pract 2002 Nov;52(482):809
unknown, likely caused by multiple factors(1,3 )
{ anatomical abnormality of temporal bone(3 )
{ viral infection leading to antigenic mimicry and persistent
theory supported by evidence of immune complex deposition in
endolymphatic sac (Otolaryngol Head Neck Surg 1996 Mar;114(3):360)
conflicting evidence regarding IgE titers to certain viruses in
{ ischemia of endolymphatic sac and inner ear(2 )
Pathogenesis:
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
z increased volume of endolymph (potassium-rich fluid) in inner ear due to
overproduction or inadequate absorption causes expansion of
z progressive distension (and/or rupture) of membranous labyrinth
(endolymphatic hydrops), which contains cochlear and vestibular apparatus(1,2 )
z vertigo and balance problems may be caused by injury to vestibular
apparatus from endolymphatic hydrops (change in the volume and/or compostion of cochlear fluid)(1 )
z hearing loss may result from injury to cochlea from endolymphatic hydrops
z presence of endolymphatic hydrops not absolute requirement for diagnosis
z distention of endolymphatic compartment (scala media) in cochlea also
{ Reissner's membrane separates endolymphatic compartment (scala
media) from perilymphatic compartment (scala vestibuli)
{ Reissner's membrane ruptures in some patients, resulting in mixture
{ shift in electrolyte balance with mixture of perilymph and endolymph
alteration of depolarization and repolarization of vestibular
disruption of hair cell motility leads to deafness
disruption of vestibular neural function leads to vertigo
Possible risk factors:
{ 7.7% patients with Meniere's disease have family history of Meniere's
disease with autosomal dominant inheritance, about 60% penetrance (J Laryngol Otol 1995 Jun;109(6):499)
z metabolic dysfunction affecting sodium and potassium balance in inner ear
Complications:
z decreased quality of life (Otol Neurotol 2001 Nov;22(6):888)
Associated conditions:
z endolymphatic hydrops (increased endolymph pressure in membranous
z Meniere's disease associated with migraine
{ among 78 patients with Meniere's disease, 56% lifetime prevalence of
{ among 78 orthopedic patients (controls), 25% lifetime prevalence of
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
{ Reference - Neurology 2002 Dec 10;59(11):1700
z Meniere's disease associated with treated hypothyroidism
{ 50 patients with Meniere's disease compared to 50 matched controls
without Meniere's disease who were evaluated for dizziness
{ 16 (32%) cases vs. 2 (4%) control were taking thyroid hormone
{ Reference - Arch Otolaryngol Head Neck Surg 2004 Feb;130(2):226
{ DynaMed commentary - conclusion should be considered hypothesis-
generating given small numbers and case-control design
z Lermoyez’s syndrome - rare variant of Meniere’s disease in which
progressive deterioration of hearing is followed by vertigo, after which hearing improves (Laryngorhinootologie 1996 Jun;75(6):372)
Chief Concern (CC):
z classic triad of symptoms(1,3 )
{ vertigo - illusion of movement of self or one's surroundings (e.g.
vertigo may present as abnormal unpleasant sensation of
patient often complains of dizziness, but whenever possible,
dizziness should be clarified since it can mean
{ progressive sensorineural hearing loss
z other common symptoms(1 )
z drop attacks - sudden unexplained falls without loss of consciousness or
History of Present Illness (HPI):
z clinical course varies between patients(2 )
z frequently presents initially with episodes of intense vertigo, then later
progressive hearing loss (low and high frequency)
z ask about frequency and duration of acute attacks and severity of
{ duration of acute attacks ranges from minutes to hours, usually 2-3
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
{ acute episodes can occur in clusters (about 6-11 per year)
{ periods of remission can last several months
z between attacks, patients may be asymptomatic or may have
z typical stages of Meniere's disease(3 )
vertigo is predominant symptom, typically rotatory or rocking
and associated with nausea and/or vomiting
pallor and sweating may occur with vertigo, but no loss of
often preceded by aura of fullness or pressure in ear or side of
head lasting 20 minutes to several hours
hearing reverts to normal between attacks
{ stage 2 - vertigo and fluctuating hearing loss
hearing loss is established, but continues to fluctuate
sensorineural deafness primarily affecting lower pitches
vertigo reaches peak severity then becomes less severe
remission is highly variable, often lasting several months
hearing loss progressively worsens, and becomes bilateral
episodes of vertigo disappear, although patient may still be
z frequency and duration of vertigo attacks
{ based on prospective cohort of 243 consecutive patients with definite
diagnosis of Meniere's disease referred to vestibular laboratory, with
disease duration ranging from recent onset to 41 years
continuous vertigo for 5% patients. continuous vertigo was
more common (21%) in patients who had Meniere's disease for
{ Reference - Arch Otolaryngol Head Neck Surg 2004 Apr;130(4):431
Medication History:
z medications that can affect vestibular system include
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
Family History (FH):
z ask about family history of Meniere's disease(1 )
Social History (SH):
ask about how condition affects quality of life, such as(1 )
General Physical:
z no physical exam findings specific to Meniere's disease(1 )
z blood pressure (supine and standing)(1 )
z hearing tests (Weber and Rinne's tests)(1 )
z examine cervical spine for vertigo associated with cervical spondylosis and
z for patients presenting with vertigo, consider evocative testing (Hallpike
maneuver) to rule out benign positional paroxysmal vertigo (BPPV)
z examine cranial nerves to consider other causes of vertigo, deafness and
z Romberg test and finger-nose test for assessment of gait and coordination
z evaluate deep tendon reflexes and sensation for signs of peripheral
Making the diagnosis:
z clinical diagnosis based on history and physical exam(1 )
z American Academy of Otolaryngology-Head and Neck Surgery diagnostic
{ vertigo ≥ 2 spontaneous episodes lasting ≥ 20 minutes during single
{ tinnitus with or without perception of aural fullness
{ sensorineural hearing loss confirmed by audiometry on at least 1
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
occasion (may be difficult to confirm in early stages of disease(1 ))
{ (symptoms may not be present simultaneously or in same pattern)
{ Reference - Otolaryngol Head Neck Surg 1995 Sep;113(3):181 as
referenced in(1,2 ), commentary can be found in Otolaryngol Head Neck Surg 1996 Jun;114(6):835
Rule out:
z other causes of vertigo
{ benign paroxysmal positional vertigo (common cause of vertigo)(1,3 )
{ vestibular neuronitis - sudden onset of acute vertigo, nausea and
infective labyrinthitis(3 ) - vertigo only occurs in acute phase
{ secondary or delayed endolymphatic hydrops - otosclerosis, trauma,
labyrinthine fistula or thrombosis(1,3 )
{ cerebellopontine tumors(1,3 ), such as acoustic neuroma (rare cause of
vascular lesions(1,3 ), such as vascular loop compression of cranial
z other causes of unsteadiness(3 )
{ active chronic suppurative otitis media
{ peripheral neuropathy as cause of unsteadiness
z Cogan's syndrome (keratitis, hearing deficit, tinnitus, vertigo, polyarteritis
{ vasculitis manifestations relatively uncommon in retrospective review
of 60 patients with Cogan syndrome (Mayo Clin Proc 2006 Apr;81(4):483
EBSCOhost Full Text)
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
{ case presentation of Cogan syndrome can be found in N Engl J Med
EBSCOhost Full Text Testing to consider:
z audiometry for diagnostic confirmation of sensorineural hearing loss
z glycerol dehydration test may be specific audiometric test but may be
z MRI of cerebellum and pontine angle might be used to rule out tumor or
z consider prolactin level, especially in severe cases
{ study of 42 Meniere's patients hospitalized for neurectomy of
vestibular nerve for relief of incapacitating vertigo
{ 14 (33%) had hyperprolactinemia (> 20 mcg/L), 6 were further
investigated and had prolactinoma confirmed by MRI
{ Reference - Neuropsychopharmacology 2002 Jan;26(1):135 in BMJ
Imaging studies:
z MRI of temporal bone may show abnormal findings in Meniere's
{ based on MRI studies in 21 patients with Meniere's disease (12 had
unilateral, 9 had bilateral disease) compared to images from 30
{ endolymphatic duct appeared less visible in patients with Meniere's
{ distance from posterior semicircular canal to posterior temporal
border bilaterally reduced in patients with Meniere's disease
{ no differences between symptomatic and asymptomatic ears in
{ no relationship between visualization of endolymphatic duct and
disease progression or response to treatment
{ Reference - Acta Otolaryngol 2000 Aug;120(5):615
EBSCOhost Full Text
z American College of Radiology (ACR) Appropriateness Criteria for vertigo
and hearing loss can be found at National Guideline Clearinghouse 2006 Sep 4:9602
Other diagnostic testing:
z audiometry
{ hearing loss confirmed by audiometry to be sensorineural hearing loss
is part of diagnostic criteria for Meniere's disease(1 )
audiometric assessment may be impractical during acute attack(1 )
hearing loss may be transient in early stages of disease(1 )
{ test loudness recruitment
defined as abnormal growth of perceived loudness with
must have normal hearing in unaffected ear to detect
abnormality (by comparison) in affected ear
100% sensitive in series of 200 patients with Meniere's disease
(Acta Otolaryngol 1959 Nov-Dec;50:472), but not specific for Meniere's disease
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
Reference - Otolaryngol Clin North Am 1997 Dec;30(6):987
{ glycerol dehydration test
measures audiometric response to oral dose of glycerol(3 )
improvement in scores for hearing low frequency sound and
glycerol dehydration test reported to have 47-60% sensitivity
and 93-98% specificity for endolymphatic hydrops (Otolaryngol Clin North Am 1997 Dec;30(6):987)
results of glycerol test may be affected by suggestion
patients with typical Meniere's syndrome randomized to
have glycerol test done twice with same dose of glycerol but with different flavors, once with suggestion that
hearing would improve and once with suggestion that hearing would worsen
audiologist unaware of patient instructions (suggestion)
patients usually responded as instructed
Reference - J Otolaryngol 1979 Apr;8(2):145, also
published in Adv Otorhinolaryngol 1979;25:49
z electrocochleography
{ highly characteristic waveform in hydrops(3 )
{ negative results may occur in early or late stages of disease(3 )
{ electrocochleography may be useful for diagnosis of endolymphatic hydrops
based on prospective study of electrocochleography recordings
from > 500 ears with diagnosis suggestive of Meniere's disease
Reference - Acta Otolaryngol 2000 Jun;120(4):480
EBSCOhost Full Text
{ EMLA cream may reduce discomfort associated with transtympanic electrocochleography (level 2 [mid-level] evidence)
46 patients having unilateral transtympanic
electrocochleography were randomized to EMLA cream as
EMLA cream associated with less discomfort during procedure
Reference - Auris Nasus Larynx 1998 May;25(2):137
z anti-68kd antibody may be present in inner ear material of patients with
Meniere's disease (Laryngoscope 1995 Dec;105(12 Pt 1):1347), commentary can be found in Laryngoscope 1997 Mar;107(3):405
Prognosis:
z normal lifespan (Meniere's disease is not fatal)
z quality of life affected, especially if progressive hearing loss or intractable
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
z long-term outcomes appear similar with or without surgical intervention
{ based on retrospective study comparing 83 patients with Meniere's
disease who had surgery and 50 patients who declined surgery
{ control of vertigo among non-surgical patients
71% at last follow-up of mean 8.3 years
{ control of vertigo among surgical patients
40% at 2 years after endolymphatic subarachnoid shunt
70% at mean 8.7 years after endolymphatic subarachnoid
93% at mean 4.4 years after neurectomy
{ Reference - Otolaryngol Head Neck Surg 1989 Jan;100(1):6
Treatment overview:
z refer to ear, nose and throat (ENT) specialist to confirm diagnosis
z explanation of disorder and variable prognosis
z hearing amplification may be only clearly beneficial treatment
z treatments to provide rapid relief during acute attack may include
anticholinergic, antihistamine, benzodiazepine or phenothiazine (grade C recommendation [lacking direct evidence])
z low-salt diet plus diuretics reported to improve vertigo and delay hearing
loss (level 3 [lacking direct] evidence)
z no clear evidence that diuretics have any beneficial effects on Meniere’s
disease, but triamterene 50 mg/hydrochlorothiazide 25 mg (Dyazide)
associated with improvement in vestibular symptoms in 1 trial (level 2 [mid-level] evidence)
{ self-management with vestibular rehabilitation may reduce symptoms
associated with Meniere's disease (level 2 [mid-level] evidence)
{ vestibular rehabilitation improves subjective dizziness in patients with
unilateral peripheral vestibular dysfunction (level 1 [likely reliable] evidence) (in trials not specific to Meniere's disease)
z betahistine hydrochloride (Serc) 16 mg 2-3 times daily might reduce
{ insufficient evidence regarding betahistine for Meniere's disease,
{ betahistine dihydrochloride may be effective for vertigo due to
Meniere's disease (level 2 [mid-level] evidence)
{ betahistine may be more effective than prochlorperazine maleate or
flunarizine but less effective than trimetazidine (level 2 [mid-level] evidence)
{ generic betahistine available in United States by prescription through
z intratympanic gentamicin may reduce frequency of or eliminate vertigo
attacks (level 2 [mid-level] evidence)
z multiple other medications have very limited evidence of benefit
z Meniett device (portable low-intensity alternating pressure generator)
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
appears safe and effective for vertigo symptoms (level 2 [mid-level] evidence)
z various hearing-sparing surgeries appear to have similar efficacy to each
other, but endolymphatic shunt procedure appears no better than placebo
surgery (level 2 [mid-level] evidence)
z dietary modification in Meniere's disease not evaluated in randomized trials,
z low salt diet (< 2 g/day) has been recommended (grade C recommendation [lacking direct evidence])
{ thought to be useful for decreasing production and accumulation of
endolymph for prevention of vertigo(2,4 )
{ not evaluated in randomized trials(4 )
{ DynaMed commentary -- diet expected to have very little influence on
{ low-salt diet plus diuretics reported to improve vertigo and delay hearing loss (level 3 [lacking direct] evidence)
based on uncontrolled retrospective study
54 patients with Meniere's disease who were treated with
diuretics and low-salt diet were evaluated
79% had complete or substantial control
19% had limited or insignificant improvements
Reference - Otolaryngol Head Neck Surg 1993 Oct;109(4):680
similar results reported in series of 500 consecutive patients
treated with low sodium diet and diuretics, in review of 20 years of practice at University of Michigan (Ann Otol Rhinol
Activity:
moving around after acute attack may promote vestibular rehabilitation(1 )
z vestibular rehabilitation exercises
{ may be useful for patients who have(1 )
acute attacks of vertigo that are far apart and have motion-
recurrent motion-provoked imbalance despite treatment
{ self-management with vestibular rehabilitation may reduce symptoms associated with Meniere's disease (level 2 [mid- level] evidence)
based on randomized trial without attention control
360 patients with Meniere's disease were randomized to receive
vestibular rehabilitation self-management booklet vs. symptom
control self-management booklet vs. waiting list control
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
vestibular rehabilitation consisted of provoking controlled
dizziness by making repeated head movements to promote neurological and psychological habituation
symptom control consisted of using applied relaxation,
challenging negative beliefs, and lifestyle modification to reduce
both intervention groups reported greater enablement
vestibular rehabilitation associated with reduced
symptoms, anxiety, handicap and negative beliefs
symptom control associated with reduced handicap
37.5% vestibular rehabilitation vs. 39.2% symptom control vs.
15.8% control group reported improvement at 6 months
Reference - Psychosom Med 2006 Sep-Oct;68(5):762,
commentary can be found in Evid Based Med 2007 Aug;12
{ other trials showing reduction in dizziness symptoms with vestibular
rehabilitation were not specific to Meniere's disease
vestibular rehabilitation may improve subjective dizziness in patients with unilateral peripheral vestibular dysfunction (level 2 [mid-level] evidence)
based on Cochrane review with clinical heterogeneity
systematic review of 21 randomized trials evaluating
vestibular rehabilitation in community-dwelling adults
with symptomatic unilateral peripheral vestibular dysfunction
vestibular rehabilitation was compared to sham
intervention (control), non-vestibular rehabilitation
interventions or other forms of vestibular rehabilitation
comparing vestibular rehabilitation vs. control/placebo
methods of vestibular rehabilitation varied across
trials so unclear if meta-analysis is appropriate despite lack of statistical heterogeneity
48.9% vestibular rehabilitation vs. 26.5%
control/placebo patients had subjective improvement in dizziness in analysis of 4 trials with 565 patients (p < 0.00001, NNT 5)
movement-based vestibular rehabilitation less effective
than physical maneuvers for BPPV for short-term cure
rate (62% vs. 93%, p = 0.004) in 1 trial with 71 patients
Reference - systematic review last updated 2007 Aug 22
(Cochrane Library 2007 Issue 4:CD005397)
vestibular rehabilitation (based on head and eye exercises, delivered by primary care nurse) reduces symptoms of chronic dizziness that may be of labyrinthine origin (level 1 [likely reliable] evidence)
170 patients with dizziness for at least 2 months
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
(excluding patients with documented nonlabyrinthine cause of dizziness) and dizziness in response to head and
eye exercise movements were randomized to vestibular rehabilitation vs. control (3-month delay)
vestibular rehabilitation included 30-40 minutes with
trained nurse for instructions on head and neck exercises
to be done twice daily for 12 weeks or until exercises no longer provoked dizziness, and follow-up telephone calls
10 patients dropped out but intention-to-treat analysis
at 3 months, vestibular rehabilitation significantly
improved scores for vertigo symptoms (9.9 vs. 13.3, with
3-point difference considered clinically significant), movement-provoked dizziness (14.6 vs. 20.7 on 36-point
scale), postural stability, and dizziness handicap (31.1 vs. 35.9 on 75-point scale)
Reference - Ann Intern Med 2004 Oct 19;141(8):598
EBSCOhost Full Text, editorial can be found in Ann EBSCOhost Full Text, commentary can be found in Ann Intern Med 2005 Feb 15;142(4):309 EBSCOhost Full Text, Am Fam
Physician 2005 Jul 15;72(2):330 full-text
vestibular rehabilitation may reduce symptoms of dizziness and vertigo (level 2 [mid-level] evidence)
based on randomized trial with multiple methodologic
159 patients from 10 general practices with diagnoses of
or medications prescribed for dizziness were identified
average duration of dizziness 6-8 years
patients were excluded if unable to perform vigorous
head and body movements, dizziness was non-vestibular, or patients had multiple or serious central disorders
patients with dizziness (idiopathic or due to vestibular
dysfunction) randomized to Vestibular Rehabilitation
exercises (40-minute session given by nurse that included education about causes of dizziness, standard
head and body movements, and training in relaxation) vs. regular medical treatment
several serious challenges to validity of study include
27% lost to follow up at 6 months (37% treatment
positive effect noted at 6-month follow-up in treatment
group for all areas measured except perceived handicap
26% vs. 17% patients rated themselves as better
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
29% vs. 23% patients rated themselves as better
Reference - Br J Gen Pract 1998 Apr;48(429):1136 PDF,
editorial can be found in Br J Gen Pract 1998 Apr;48(429):1128 PDF, commentary can be found in Br J Gen
Pract 1998 Jul;48(432):1434 PDF, J Fam Pract 1998 Sep;47(3):176
Counseling:
z advice for patients with Meniere's disease(1 )
{ keep medication easily available and accessible, especially in patients
{ avoid high risk activities (e.g. driving, operating dangerous
in United Kingdom, patients required to inform Driver and
Vehicle Licensing Agency of diagnosis, driving restrictions depend on type of license and symptom control
{ patients with symptomatic tinnitus should avoid silent environments
z psychological support in Meniere's disease may have positive effect on
disease management, but not evaluated in randomized trials(1,4 )
z self-management through information booklets may reduce symptoms associated with Meniere's disease (level 2 [mid-level] evidence)
{ based on randomized trial without attention control
{ 360 patients with Meniere's disease were randomized to receive
vestibular rehabilitation self-management booklet vs. symptom control self-management booklet vs. waiting list control
{ vestibular rehabilitation consisted of provoking controlled dizziness by
making repeated head movements to promote neurological and psychological habituation
{ symptom control consisted of using applied relaxation, challenging
negative beliefs, and lifestyle modification to reduce amplification of dizziness by anxiety
both intervention groups reported greater enablement than
vestibular rehabilitation associated with reduced symptoms,
symptom control associated with reduced handicap
{ 37.5% vestibular rehabilitation vs. 39.2% symptom control vs. 15.8%
control group reported improvement at 6 months
{ Reference - Psychosom Med 2006 Sep-Oct;68(5):762, commentary
can be found in Evid Based Med 2007 Aug;12(4):111
Medications:
z treatments to provide rapid relief during acute attack (grade C recommendation [lacking direct evidence])(1,3 )
{ intramuscular prochlorperazine (Compazine) for severe symptoms
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
{ oral prochlorperazine or antihistamine (e.g. cinnarizine, cyclizine,
promethazine or diazepam) for 7 days if symptoms less severe
{ reassess if symptoms do not improve after 7 days of treatment
{ for short-term use only, prolonged use can cause extrapyramidal
adverse effects, especially in elderly patients
{ no randomized trials identified to evaluate benzodiazepines,
betahistine, cinnarizine, or phenothiazines for treatment of acute
{ meclizine (Antivert) may reduce vertigo
based on randomized crossover trial (with only 4 Meniere's
31 patients with vertigo (only 4 had Meniere's disease)
randomized to meclizine 25 mg vs. placebo orally 3 times daily for 1 week each in crossover fashion
27 (87%) patients included in statistical analysis
19 (70%) vs. 10 (37%) had improvement in frequency of
18 (67%) vs. 9 (33%) had improvement in severity of
Reference - Arch Neurol 1972 Aug;27(2):129
{ glycopyrrolate (Robinul)
glycopyrrolate 2 mg twice daily as needed for 4-6 weeks (but
not placebo) associated with reduced symptoms in trial with 37 patients with Meniere's disease (Laryngoscope 1998 Oct;108
z betahistine
{ antagonist to histamine H3 receptors, used for vertigo
{ has been described as both antihistamine and vasodilator, also shown
to affect cochlear blood flow through cholinergic receptors in rats (Am
{ Serc is brand name for betahistine hydrochloride
{ preferred antivertiginous drug in Europe (Otolaryngol Clin North Am
{ consider trial of betahistine 16 mg 3 times daily for 6-12 months to
{ insufficient evidence regarding betahistine for Meniere's
based on Cochrane review of limited evidence
systematic review of 6 randomized trials evaluating betahistine
no trial had highest methodological quality, no trial assessed
most trials suggested reduction in vertigo
reductions in tinnitus were inconsistent
Reference - systematic review last updated 2000 May 22
(Cochrane Library 2001 Issue 1:CD001873)
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
{ betahistine dihydrochloride may be effective for vertigo due to Meniere's disease (level 2 [mid-level] evidence)
based on randomized trial with allocation concealment not
81 patients aged 18-65 years with recurrent vertigo due to
Meniere's disease were randomized to betahistine 16 mg vs. placebo twice daily for 3 months
betahistine associated with improvement in frequency, intensity
and duration of vertigo attacks, associated symptoms and quality of life
Reference - Eur Arch Otorhinolaryngol 2003 Feb;260(2):73
EBSCOhost Full Text
{ betahistine hydrochloride associated with improved symptoms in patients with Meniere's disease (level 2 [mid-level] evidence)
based on crossover trial with 21% dropout rate
28 patients with Meniere's disease given betahistine 32 mg vs.
placebo daily for 16 weeks then crossed over to alternate treatment after 4 week washout
betahistine associated with improved vertigo, tinnitus and
Reference - Postgrad Med J 1976 Aug;52(610):501
{ betahistine hydrochloride may be more effective than prochlorperazine maleate (level 2 [mid-level] evidence)
based on small crossover trial with high dropout rate
30 patients with confirmed Meniere's disease were given
betahistine vs. prochlorperazine for 4 months then crossed over to alternate treatment after 1 month washout
betahistine associated with better therapeutic effect than
betahistine and prochlorperazine comparable for number of
vertigo attacks in analysis of 17 patients
Reference - Ann Clin Res 1976 Aug;8(4):284
{ betahistine dihydrochloride may be more effective than flunarizine for treatment of vertigo (level 2 [mid-level] evidence)
patients with recurrent vertigo of peripheral vestibular origin
were randomized to betahistine dihydrochloride 48 mg orally vs. flunarizine 10 mg orally daily for 8 weeks
52 patients completed study and were analyzed
vertigo evaluated using Dizziness Handicap Inventory (a
validated self-assessment questionnaire, but not
previously used to evaluate anti-vertigo medications)
betahistine associated with significantly greater
improvement on Dizziness Handicap Inventory and
Reference - Acta Otolaryngol 2003 Jun;123(5):588
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
EBSCOhost Full Text
55 patients with recurrent paroxysmal vertigo characteristic of
Meniere's disease were randomized to betahistine vs.
betahistine associated with decreased duration and
severity of vertigo attacks at 1 and 2 months, number of attacks, vestibular dysfunction and cochlear symptoms
flunarizine associated with decreased duration and
severity of vertigo attacks at 1 month only
flunarizine - drowsiness, asthenia, depression
Reference - Acta Otolaryngol Suppl 1991;490:1
{ trimetazidine may be more effective than betahistine (level 2 [mid-level] evidence)
based on 2 randomized trials published in French
45 patients with possible Meniere's disease were
randomized to trimetazidine 20 mg vs. betahistine 8 mg
5 patients dropped out, 40 patients analyzed
comparing trimetazidine vs. betahistine
79% vs. 57% had improvement in overall evolution
of disease (p = 0.027, NNT 5 favoring trimetazidine)
53% vs. 24% had complete disappearance of
no differences in hearing or tinnitus
trimetazidine associated with improved vertigo intensity,
but not confirmed by analysis of available data
Reference - Ann Otolaryngol Chir Cervicofac 1990;107
Suppl 1:20 [French] as referenced in(4 )
20 patients with definite or probable Meniere's disease
were randomized to trimetazidine 20 mg vs. betahistine 8 mg given 3 times daily for 3 months
no differences in hearing, tinnitus, aural fullness, or
trimetazidine associated with increased self-reported
improvements in duration and intensity of vertigo
Reference - Ann Otolaryngol Chir Cervicofac 1990;107
Suppl 1:11 [French] as referenced in(4 )
z diuretics
{ diuretics not recommended for prevention of recurrent attacks(1 )
{ proposed mechanism of action - resorption of endolymph
{ no clear evidence that diuretics have any beneficial effects on Meniere’s disease
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
systematic review of randomized placebo-controlled trials of
no trials of high enough quality met inclusion criteria for this
3 crossover trials (Acta Otolaryngol 1967 Apr;63(4):347,
Fortschr Med 1982 Mar 11;100(10):431, ORL J Otorhinolaryngol Relat Spec 1986;48(5):287) were excluded
due to inability to extract pre-crossover results
Reference - systematic review last updated 2006 May 19
(Cochrane Library 2006 Issue 3:CD003599)
{ triamterene 50 mg/hydrochlorothiazide 25 mg (Dyazide) associated with improvement in vestibular symptoms (level 2 [mid-level] evidence)
based on double-blind crossover trial in 33 patients
no significant effect on hearing or tinnitus
Reference - ORL J Otorhinolaryngol Relat Spec 1986;48(5):287
{ low-salt diet plus diuretics reported to improve vertigo and delay hearing loss (level 3 [lacking direct] evidence)
54 patients with Meniere's disease who were treated with
diuretics and low-salt diet were evaluated
79% had complete or substantial control
19% had limited or insignificant improvements
Reference - Otolaryngol Head Neck Surg 1993 Oct;109(4):680
z intratympanic gentamicin
{ chemical labyrinthectomy (vestibular ablation)
{ used for patients who have failed conservative management and are
{ adverse effects include cochlear toxicity (hearing loss), ataxia,
{ intratympanic gentamicin may reduce frequency of or eliminate vertigo attacks (level 2 [mid-level] evidence)
22 patients with active Meniere's disease were randomized to
gentamicin 4 mL (30 mg/mL) vs. placebo injected in middle ear
every 6 weeks until symptoms controlled (maximum cumulative dose 360 mg in 12 applications or 6 months)
mean number of applications 1.5 with gentamicin vs. 2.8 with
both treatments associated with decreased mean number of
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
vertigo attacks per year compared to baseline (74 to 0 with gentamicin, 25 to 11 with placebo)
Reference - Acta Otolaryngol 2004 Mar;124(2):172
EBSCOhost Full Text
{ intratympanic gentamicin might be more effective than intratympanic dexamethasone for controlling vertigo (level 2 [mid-level] evidence)
based on small controlled trial published in Turkish
45 patients with Meniere's disease were given intratympanic
gentamicin (40 mg/mL) 0.7 mL or dexamethasone (4 mg/mL)
only 9 of 21 patients in dexamethasone group completed
gentamicin associated with 92% rate of control of vertigo
symptoms (22 patients) and 8% deterioration in hearing (2 patients)
dexamethasone associated with 67% control of vertigo
Reference - Kulak Burun Bogaz Ihtis Derg 2006;16(5):193
{ intratympanic gentamicin might be effective for achieving complete or substantial vertigo control (level 3 [lacking direct] evidence)
based on 2 systematic reviews of mostly uncontrolled cohort
systematic review of 15 prospective and retrospective cohort
studies evaluating intratympanic gentamicin in 627 patients
74.7% achieved complete (class A) vertigo control (95%
92.7% achieved complete or substantial (class B) vertigo
efficacy not affected by fixed vs. titration treatment
no clinically important or statistically significant hearing
Reference - Laryngoscope 2004 Dec;114(12):2085
systematic review of 35 studies evaluating intratympanic
gentamicin injections in patients with Meniere's disease
89% patients had complete or substantial vertigo control
(range 73-100%) in analysis of 34 studies
26% patients had hearing loss (range 0-90%) in analysis
57% patients had subjective improvement in tinnitus
pooled results for 16 studies with minimum 2 years
87% patients had vertigo improvement (range 76-
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
24% patients had hearing loss (range 0-75%)
insufficient data to determine ideal dose or method of
Reference - J Otolaryngol 2003 Dec;32(6):351
EBSCOhost Full Text
{ intratympanic gentamicin reported to be associated with long- term relief of vertigo in most patients (level 3 [lacking direct] evidence)
based on uncontrolled prospective study
103 patients with Meniere's disease treated with intratympanic
80% patients achieved complete control of vertigo
15.5% patients reported continued unsteadiness
Reference - Laryngoscope 2007 Aug;117(8):1474
{ titration method of intratympanic gentamicin injection reported to be more effective than other techniques (level 3 [lacking direct] evidence)
based on systematic review limited by heterogeneity and only
systematic review and meta-analysis of 27 studies evaluating
intratympanic gentamicin delivery technique in 980 patients with Meniere's disease
81.7% with titration method (daily or weekly doses until
onset of vestibular symptoms) in 6 studies with 269 patients, titration method more effective than other
66.7% with low-dose technique (1-2 injections with
retreatment for recurrent vertigo) in 8 studies with 253
patients, low-dose technique less effective than other techniques (p < 0.001)
76.1% with multiple daily dosing (3 times daily for ≥ 4
75% with weekly dosing (weekly injections for 4 total
70.5% with continuous microcatheter delivery in 4
rates of effective vertigo control (complete plus substantial
96.3% with titration method in 6 studies with 269
patients, titration method more effective than other techniques (p < 0.05)
86.8% with low-dose technique in 8 studies with 253
patients, low-dose technique less effective than other techniques (p = 0.05)
no significant differences with multiple daily dosing
(91.1%), weekly dosing (89.3%), or continuous (88.3%)
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
13.1% with weekly dosing in 2 trials with 84 patients,
trend toward less hearing loss than other techniques (p = 0.08)
34.7% with multiple daily dosing in 7 trials with 218
patients, associated with more hearing loss than other techniques (p < 0.02)
no significant differences with low-dose (23.7%), titration
estimated rate of profound hearing loss 6.6% overall, no
significant differences between techniques
Reference - Otol Neurotol 2004 Jul;25(4):544, commentary can
be found in Otol Neurotol 2005 May;26(3):554 (commentary can be found in Otol Neurotol 2005 Sep;26(5):1094)
{ review of intratympanic gentamicin for Meniere's disease can be
found in Laryngoscope 2000 Feb;110(2 Pt 1):236
z intratympanic latanoprost may be associated with reduction of vertigo and improvement in speech discrimination (level 2 [mid- level] evidence)
{ 10 patients aged 39-65 years with unilateral Meniere's disease were
randomized to latanoprost vs. placebo (0.2-0.4 mL) injected into
{ latanoprost associated with reduction of vertigo or dysequilibrium (p
= 0.039) and improved speech discrimination (p ≤ 0.05)
{ few patients had clinically relevant improvements (4 for vertigo, 2 for
{ no significant differences in visual analog score assessments of
{ Reference - Otolaryngol Head Neck Surg 2005 Sep;133(3):441
z intratympanic dexamethasone has very limited evidence of benefit
{ intratympanic dexamethasone injection might be effective for treatment of Meniere's disease (level 2 [mid-level] evidence)
22 patients with Meniere's disease (Shea's stage III) > 18
years old were randomized to intratympanic dexamethasone 4 mg/mL vs. placebo daily for 5 days
4 (36%) placebo patients dropped out due to need for
comparing dexamethasone (11 patients) vs. placebo (7
9 (82%) vs. 4 (57%) had completely controlled vertigo
2 (18%) vs. 2 (29%) had substantially controlled vertigo
48% vs. 20% had improvement in tinnitus
35% vs. 10% had improvement in hearing loss
48% vs. 20% had improvement in aural fullness
none of these differences were statistically significant
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
Reference - Otolaryngol Head Neck Surg 2005 Aug;133(2):285
{ intratympanic dexamethasone appears no better than placebo in late stage Meniere's disease (level 2 [mid-level] evidence)
based on small randomized crossover trial
20 patients with unilateral Meniere's disease (Shea's stage IV)
in private otology practice were randomized to intratympanic dexamethasone vs. placebo for 3 days each
no significant differences in hearing loss or tinnitus
Reference - Am J Otol 1998 Mar;19(2):196
DynaMed commentary -- this study involved patients in late
stage Meniere's disease after vertigo had resolved, so does not
provide information regarding treatment of vertigo
{ relief of vertigo in case series cannot be distinguished from spontaneous remission (level 3 [lacking direct] evidence)
dexamethasone 4 mg/mL by intratympanic injection over 4
weeks reported to provide complete relief of vertigo in 11 of 21 patients (52%) at 3 months and 9 of 21 patients (43%) at 6
months in prospective case series (Laryngoscope 2001 Dec;111(12):2100)
dexamethasone by intratympanic injections plus intramuscular
routes did not significantly improve symptoms (aural fullness,
hearing loss, tinnitus and vertigo) in series of 17 patients with Meniere's disease; 76% achieved sufficient control of vertigo,
but this might be expected from spontaneous remission (ORL J Otorhinolaryngol Relat Spec 2000 May-Jun;62(3):117)
z interventions with limited evidence of efficacy in single trials
{ combination cinnarizine plus dimenhydrinate appears to have similar efficacy as betahistine dimesylate (level 2 [mid-level] evidence)
based on randomized trial without placebo control
82 patients with Meniere's disease for ≥ 3 months with
paroxysmal vertigo attacks, cochlear hearing loss and tinnitus were randomized to combination tablet containing cinnarizine
20 mg plus dimenhydrinate 40 mg (Arlevert) vs. betahistine dimesylate 12 mg 3 times daily for 12 weeks
both treatments improved vertigo symptoms, tinnitus, and
associated vegetative symptoms, but no significant differences between groups
cinnarizine plus dimenhydrinate associated with improved
Reference - Int Tinnitus J 2002;8(2):115
{ oral prednisone may improve vertigo episodes and tinnitus (level 2 [mid-level] evidence)
based on small open-label randomized trial
16 patients with Meniere's disease with limited vertigo control
and severe disability were given diphenidol 25 mg/day plus
acetazolamide 250 mg every 48 hours and randomized to prednisone 0.35 mg/kg orally vs. no additional treatment daily for 18 weeks
prednisone associated with reduced frequency and duration of
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
no differences in aural fullness or hearing
Reference - Otol Neurotol 2005 Sep;26(5):1022
{ hydroxyethylrutosides associated with improved audiometric findings and trend toward symptom improvement (level 2 [mid-level] evidence)
based on randomized crossover trial with non-significant trend
39 patients with well-defined Meniere's disease were
randomized to hydroxyethylrutosides 2 g vs. placebo for 3 months and then crossed over to alternate treatment
hydroxyethylrutosides improved audiometric findings for air and
bone conduction at frequencies of 250, 500, 1,000, 2,000 and
hydroxyethylrutosides associated with trend for greater
Reference - J Laryngol Otol 1984 Mar;98(3):265
{ diphenidol associated with improved vertigo, dizziness or unsteadiness (level 2 [mid-level] evidence)
based on crossover trial in 24 patients with Meniere's disease
Reference - Acta Otolaryngol Suppl 1975;330:120
z interventions with very limited evidence of efficacy in case series
{ methotrexate reported to be associated with improved hearing loss and vertigo (and tinnitus to a lesser degree) (level 3 [lacking direct] evidence)
based on 2 case series of 64 patients with Meniere's disease
and partial response to prednisone 1 mg/kg/day
Reference - J Rheumatol 2001 May;28(5):1037, Ann Otol
Rhinol Laryngol 2000 Aug;109(8 Pt 1):710
{ general anesthesia reported to be effective (level 3 [lacking direct] evidence)
patients with vertigo unresponsive to low salt diet, diuretic and
stress reduction were treated with single injection of
combination droperidol plus fentanyl (Innovar)
58% reported long-lasting relief of vertigo at 2-8 years
Reference - Acta Otolaryngol 1999 Mar;119(2):189
EBSCOhost Full Text
z scopolamine patch not clearly effective in Meniere's disease (level 2 [mid-level] evidence)
{ 30 patients with acute peripheral vertigo (including 16 with Meniere's
disease) were assigned to 2 placebo patches, 1 placebo and 1
scopolamine 0.5 mg transdermal patch, or 2 scopolamine patches
{ treatment with 1 patch was modestly more effective than placebo for
patient-reported efficacy but not statistically significant
{ treatment with 2 patches associated with 36% discontinuation rate
{ Reference - J Otolaryngol Otol 1985 Jul;99(7):653
z famciclovir appears no more effective than placebo for symptom
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
control in Meniere's disease (level 2 [mid-level] evidence)
{ 23 patients with Meniere's disease were randomized to famciclovir vs.
{ 25% famciclovir vs. 18% placebo patients had reduced number of
{ all patients had improvements in dizziness and health-related quality
{ Reference - Otolaryngol Head Neck Surg 2004 Dec;131(6):877
Surgery:
z hearing-sparing surgery (for patients with good hearing)
most commonly used conservative surgical intervention in
endolymphatic shunt procedure appears no better than placebo surgery (level 2 [mid-level] evidence)
30 patients with Meniere's disease for 6 months to 5
years and history of typical attacks (fluctuating hearing loss, tinnitus and vertigo) occurring at least once every 2
weeks were randomized to endolymphatic sac shunt surgery draining into mastoid cavity vs. simple
mastoidectomy (placebo surgery not expected to have any effect on vestibular or cochlear system)
73% active surgery group vs. 80% placebo surgery group
were judged to have benefitted from surgery at 12
both groups had considerable improvement in all
symptoms but no significant differences between groups
Reference - Arch Otolaryngol 1981 May;107(5):271, also
published in Ann N Y Acad Sci 1981;374:820
3-year follow-up found 70% improvement in both groups
and no significant differences between groups (Am J Otol
7-year follow-up found 70% improvement in both groups
and no significant differences between groups (Ann Otol Rhinol Laryngol 1986 Jan-Feb;95(1 Pt 1):32)
9-year follow-up found 70% improvement in both groups
and no significant differences between groups (Am J Otol 1989 Jul;10(4):259)
retrospective reevaluation using different statistical
analysis reports effectiveness for endolymphatic shunt (Otolaryngol Head Neck Surg 2000 Mar;122(3):340)
endolymphatic sac shunt and ventilating tube insertion appear similarly effective (level 2 [mid-level] evidence)
29 patients aged 27-71 years with Meniere's disease
were randomized to endolymphatic sac shunt vs. ventilating tube inserted in tympanic membrane
both treatments associated with significant reductions in
dizzy spells at 6 and 12 months, but no differences
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
no differences between groups in hearing or tinnitus, but
2 patients in shunt group developed severe hearing loss
Reference - Acta Otolaryngol 1998 Nov;118(6):769
EBSCOhost Full Text
endolymphatic subarachnoid shunt reported to be effective for long-term control of vertigo in > 50% patients (level 3 [lacking direct] evidence)
234 patients with Meniere's disease treated with
endolymphatic subarachnoid shunt surgery with at least
among 147 patients (63%) who did not require additional
surgery to control vertigo, 93% reported no dizziness or
among 40 patients (17%) who only required revisions of
endolymphatic sac shunt, 96% reported no dizziness or mild to no disability
Reference - Otolaryngol Head Neck Surg 1993 Jul;109
endolymphatic mastoid shunt operation reported to be effective (level 3 [lacking direct] evidence)
81% had substantial control of vertigo
19% had clinically important hearing improvement
Reference - Clin Otolaryngol 1994 Jun;19(3):261
endolymphatic subarachnoid shunt reported to be as effective as endolymphatic mastoid shunt (level 3 [lacking direct] evidence)
based on retrospective questionnaire study
196 of 346 patients who had endolymphatic sac surgery
no significant differences in outcomes comparing
endolymphatic subarachnoid shunt vs. endolymphatic
endolymphatic mastoid shunt reported to have lower
Reference - Am J Otol 1987 Jul;8(4):275
endolymphatic sac decompression appears as effective as endolymphatic mastoid shunt (level 2 [mid-level] evidence)
88 patients with Meniere's disease treated with
endolymphatic mastoid shunt and 108 patients treated with endolymphatic sac decompression
both procedures appeared equally effective for
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
reducing incidence and severity of vertigo attacks (67% with endolymphatic mastoid shunt vs. 66%
Reference - Otolaryngol Head Neck Surg 2007
endolymphatic sac-vein decompression reported to control vertigo and improve functional level (level 3 [lacking direct] evidence)
68 patients with Meniere's disease treated with
endolymphatic sac-vein decompression were
functional level improved in 81%, remained stable
hearing class improved in 18%, remained stable in
Reference - Otolaryngol Head Neck Surg 2003
goal is to disconnect diseased labyrinth from brainstem while
risks of neurosurgery in posterior cranial fossa include injury to
cochlear nerve, facial nerve, and anterior inferior cerebellar
vestibular nerve section may improve vertigo more with less hearing loss than intratympanic gentamicin (level 2 [mid-level] evidence)
25 patients with Meniere's disease treated with
gentamicin injection and 39 patients treated with
95% vestibular nerve section patients had good to
excellent control of vertigo vs. 80% gentamicin patients
degree of postprocedure hearing loss greater with
Reference - Laryngoscope 2004 Feb;114(2):216
{ other less commonly performed hearing-sparing surgeries(3 )
z surgical options for patients with poor hearing
indicated in patients with end stage bilateral Meniere's disease
extirpation of labyrinth to control vertigo
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
labyrinthectomy associated with 98.8% effectiveness for
relieving vertigo in series of 81 patients (Laryngoscope 1996
{ cochleosacculotomy - destructive to hearing(3 )
complications can include hearing loss, facial nerve paralysis,
vestibular neurectomy associated with 97.8% effectiveness for
relieving vertigo in series of 45 patients (Laryngoscope 1996
{ translabyrinthine vestibular neurectomy - destructive to hearing(3 )
Consultation and referral:
z refer to ear, nose and throat (ENT) specialist to confirm diagnosis and/or if
z multidisciplinary support team may be useful for disease management and
{ ENT specialist - can provide additional treatment options in patients
{ physical therapist - can teach vestibular rehabilitation techniques to
{ hearing therapist - can provide support and self-care advice for
{ audiologist - can provide confirmation of sensorineural hearing loss
and self-care advice for management of tinnitus, can help with
{ counselor, psychologist or psychotherapist - can help patient cope
Other management:
z Meniett device
{ portable low-intensity alternating pressure generator used to control
{ Meniett device appears safe and effective for vertigo symptoms (level 2 [mid-level] evidence)
based on randomized trial without complete intention-to-treat
67 patients aged 33-71 years with unilateral cochleovestibular
Meniere's disease had tympanostomy tube placed in affected ear and were randomized to self-administered treatment with
Meniett device vs. placebo 3 times daily for 4 months
patients had ≥ 2 definitive vertigo attacks per month for 2
months prior to study entry, despite ≥ 3 months treatment with
low-sodium diet with or without diuretics
placebo device identical to Meniett device but exerted no
Meniett device group associated with significantly less severe
vertigo, fewer days with definitive vertigo and fewer sick days
Meniett device not associated with any complications
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
Reference - Arch Otolaryngol Head Neck Surg 2004 Jun;130
results of 2-year unblinded follow-up of 61 patients using
patients advised to follow low-sodium diet, use Meniett
device 3 times daily and maintain patent tympanostomy tube in affected ear
67% patients reported remission or greatly improved
24% patients dropped out to receive surgery
Reference - Arch Otolaryngol Head Neck Surg 2006
{ Meniett device may improve symptoms associated with Meniere's disease (level 2 [mid-level] evidence)
56 patients aged 20-65 years with active Meniere's disease and
hearing loss of 20-65 dB were randomized to Meniett device vs. placebo gadget
Meniett device associated with improvements in frequency and
intensity of vertigo, dizziness, aural pressure and tinnitus vs.
placebo, as measured by visual analog scales
Reference - Acta Otolaryngol Suppl 2000;543:99
EBSCOhost Full Text
{ Meniett device may reduce vestibular symptoms in patients with Meniere's disease (level 2 [mid-level] evidence)
40 patients aged 20-65 years with active Meniere's disease and
≥ 8 attacks in previous year were randomized to Meniett device vs. placebo ventilation tube
Meniett device associated with improvements in function and
visual analog scale evaluation, and trend toward reduction in vertigo episodes
Reference - Otol Neurotol 2005 Jan;26(1):68, also published in
Ugeskr Laeger 2006 Jan 23;168(4):378 [Danish]
z neither transcutaneous nerve stimulation nor applied relaxation appear to be effective for improving tinnitus, dizziness or hearing ability (level 2 [mid-level] evidence)
{ 20 patients with Meniere's disease were given transcutaneous nerve
stimulation vs. applied relaxation and then crossed over to alternate treatment
{ no significant differences between groups in reducing tinnitus or
dizziness, or increasing hearing ability
{ Reference - Br J Audiol 1994 Jun;28(3):131
z consider sound therapy or relaxation techniques in patients with
{ usually provided by compact disc or tape that plays soothing and
relaxing sounds to distract from tinnitus
{ reduces difference between tinnitus sounds and background sounds
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
References including Reviews and Guidelines
General references used:
z 1. Clinical Knowledge Summaries. Meniere's disease. Clinical Knowledge
z 2. Minor LB, Schessel DA, Carey JP. Meniere's disease. Curr Opin Neurol.
z 3. Saeed SR. Fortnightly review. Diagnosis and treatment of Meniere's
disease. BMJ. 1998 Jan 31;316(7128):368-72.
EBSCOhost Full Text
z 4. Clinical Evidence 2007 Mar (search date 2006 Jan)
z MEDLINE search 2007 Nov 16 using PubMed Clinical Queries (therapy) for
"meniere OR (endolymphatic hydrops)" Click for Details
Reviews:
z review can be found in Lancet 2008 Aug 2;372(9636):406
z review can be found in Lancet 2005 Dec 17;366(9503):2137
EBSCOhost Full Text, commentary can be found in Lancet 2006 Mar EBSCOhost Full Text
z review can be found in Am Fam Physician 1997 Mar;55(4):1185
EBSCOhost Full Text
z review can be found in Hospital Medicine 1999;60(8):574
z review of treatment of Meniere's disease can be found in Clin Otolaryngol
EBSCOhost Full Text
z review of medical treatment for Meniere's disease can be found in Acta
EBSCOhost Full Text
z review of vertigo can be found in Am Fam Physician 2005 Mar 15;71
z review of initial evaluation of vertigo can be found in Am Fam Physician
2006 Jan 15;73(2):244, correction can be found in Am Fam Physician 2006
Guidelines:
z American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS)
Committee on Hearing and Equilibrium (CHE) guidelines on Meniere's disease can be found in Otolaryngol Head Neck Surg 1995 Sep;113(3):181,
commentary can be found in Otolaryngol Head Neck Surg 1996 Jun;114(6):835
Patient information:
z handout from EBSCO Publishing Health Library PDF or in Spanish PDF
z handout from American Academy of Family Physicians or in Spanish
z handout on vertigo can be found in Am Fam Physician 2006 Jan 15;73
z handout on vertigo can be found in Am Fam Physician 2005 Mar 15;71
z information on vestibular rehabilitation therapy from Chicago Dizziness and
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
z DynaMed topics are created and maintained by the DynaMed Editorial Team.
z Over 500 journals and evidence-based sources (DynaMed Content Sources) are
monitored directly or indirectly using a 7-step evidence-based method for
systematic literature surveillance. DynaMed topics are updated daily as newly discovered best available evidence is identified.
Special acknowledgments:
z Minh-Thu Tran provided assistance with formatting and literature review.
Competing interests:
z Each participating member of the DynaMed Editorial Team has declared no
competing interests (financial or otherwise) related to this topic.
Please give us your feedback by clicking on the link below to send an e-mail to DynaMed:
http://dynaweb.ebscohost.com/Detail.aspx?id=113932&sid=3a01e5d1-775e-4390-a8c. 20/10/2008
Official Journal of the European Communitiesadapting to technical progress for the 27th time Council Directive 67/548/EEC on theapproximation of laws, regulations and administrative provisions relating to the classification,packaging and labelling of dangerous substances(*)THE COMMISSION OF THE EUROPEAN COMMUNITIES,Having regard to the Treaty establishing the EuropeanThe texts in Annexes I a
CYPROHEPTADINE, PIZOTIFEN AND AMITRYPTILINE AS PROPHYLACTIC THERAPY IN CYCLIC VOMITING SYNDROME S. Martinazzi, M. Fuoti, M. Brusati, A. Ravelli University Department of Pediatrics, Children’s Hospital, Spedali Civili – Brescia (Italy) BACKGROUND AND AIM. Cyclic vomiting syndrome (CVS) is a functional gastrointestinal disorder of unknown origin that causes severe recurrent attack